Vivos Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Skaff Michael C, was filed 02 Apr 2026.
Vivos Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Vivos Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. 3 insiders have disclosed 4 filings since 7 November 2025.
Every open-market trade in the period is a purchase: 2 purchases worth €1.6M, from 1 insider, and not a single sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 major shareholder. One trade stands out by size: a purchase of €1.2M from Skaff Michael C, disclosed on 2 April 2026.
The last purchase on record was published on 2 April 2026, which is 220 days ago. Typically, a trade is published a median of 14 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
Across the 3,183 companies tracked on its exchange, the median is 24 filings; at 4 filings, this issuer sits below that mark. Over the whole record (from 2020), the tally stands at 17 purchases and no sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 17.4 m USD and net income of -21.2 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- -65.4%Entry US$1.31 · Close at T+90 US$0.45
- -82.2%Entry US$13.38 · Close at T+365 US$2.38
- -71.7%Entry US$138.75 · Close at T+365 US$39.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Vivos Therapeutics, Inc. Buy (bullish), based on 2 analysts. Average price target: US$1.93.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 85,910 shares@ US$0.5821.76% mcap34.1% of flowPreferred StockSEC:0001493152-26-043383:0
- 250,000 shares@ US$0.413.58% mcap95.4% of flowCommon StockSEC:0001493152-26-040238:0
- 1,044,777 shares@ US$1.3477.2% of flowCommon StockSEC:0002074003-26-000008:0Canonical exit: 29 Jun 2026 (T+90)
- 308,848 shares@ US$1.3422.8% of flowCommon StockSEC:0002074003-26-000008:1Canonical exit: 29 Jun 2026 (T+90)
- 10,000 shares@ US$0.543.5% of flowCommon StockSEC:0001493152-23-021751:1Canonical exit: 14 Sept 2023 (T+90)
- 5,000 shares@ US$0.531.7% of flowCommon StockSEC:0001493152-23-021751:2Canonical exit: 14 Sept 2023 (T+90)
- 14,000 shares@ US$0.535.3% of flowCommon StockSEC:0001493152-23-021910:0Canonical exit: 18 Sept 2023 (T+90)
- 21 shares@ US$0.500.0% of flowCommon StockSEC:0001493152-23-021751:0Canonical exit: 13 Sept 2023 (T+90)
- 10,000 shares@ US$0.493.5% of flowCommon StockSEC:0001493152-23-021525:0Canonical exit: 12 Sept 2023 (T+90)
- 20,000 shares@ US$0.507.3% of flowCommon StockSEC:0001493152-22-036727:0Canonical exit: 23 Mar 2023 (T+90)
- 4,000 shares@ US$1.834.8% of flowCommon StockSEC:0001493152-22-015773:1Canonical exit: 30 Aug 2022 (T+90)
- 8,000 shares@ US$2.0311.8% of flowCommon StockSEC:0001493152-22-015773:0Canonical exit: 29 Aug 2022 (T+90)
- 5,000 shares@ US$4.3114.3% of flowCommon StockSEC:0001493152-21-023354:0Canonical exit: 20 Dec 2021 (T+90)
- 5,000 shares@ US$3.0010.0% of flowCommon StockSEC:0001493152-21-020536:0Canonical exit: 15 Nov 2021 (T+90)
- 1,000 shares@ US$5.294.6% of flowCommon StockSEC:0001493152-21-012902:0Canonical exit: 23 Aug 2021 (T+90)
- 4,000 shares@ US$5.3813.7% of flowCommon StockSEC:0001493152-21-012901:0Canonical exit: 23 Aug 2021 (T+90)
- 1,000 shares@ US$7.38Common StockSEC:0001493152-20-024301:0Canonical exit: 24 Mar 2021 (T+90)
- 1,000 shares@ US$7.2669Common StockSEC:0001493152-20-024277:0Canonical exit: 23 Mar 2021 (T+90)
- 500 shares@ US$8.50Common StockSEC:0001493152-20-023466:0Canonical exit: 11 Mar 2021 (T+90)
19 of 19 declarations
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. is a United States-based publicly traded company listed on the NASDAQ under the ticker VVOS. For French-, Belgian- and Swiss-based investors, it sits in the healthcare and life sciences universe, specifically in medical devices and sleep-disorder treatment services. The company was founded in 2016 and is headquartered in Littleton, Colorado, United States. Its strategic positioning is built around a non-invasive, non-surgical, and non-pharmaceutical approach to obstructive sleep apnea (OSA), a large and clinically significant market where standard solutions such as CPAP are not always well tolerated.
Vivos’ business model centers on proprietary diagnostic and therapeutic solutions for sleep-related breathing disorders. Its core offerings include oral appliance therapies such as the DNA appliance and the Vivos CARE system, complemented by diagnostic tools including VivoScore. The company has historically targeted dentists and other healthcare professionals trained to deliver its protocols, while more recently expanding its go-to-market model through provider partnerships, sleep-center affiliations, and targeted acquisitions. Management has described this evolution as a pivot toward a more scalable, provider-based distribution strategy.
Read moreShow less
From a competitive standpoint, Vivos operates in a niche but potentially attractive segment at the intersection of dental sleep medicine, respiratory care, and medical devices. Its differentiation lies in positioning itself as an alternative to conventional OSA management, particularly for patients seeking a less invasive option than positive airway pressure devices or surgery. Regulatory and clinical validation matters materially in this space, and Vivos has highlighted FDA clearances for certain products and ongoing clinical data as part of its investment case. That said, the company remains a relatively small player, so execution risk, physician adoption, reimbursement dynamics, and commercialization efficiency remain key variables.
Recent developments have been meaningful. In 2025, Vivos announced and completed the acquisition of The Sleep Center of Nevada, described by the company as the largest operator of medical sleep centers in Nevada. Management has framed this transaction as part of a broader national expansion strategy aimed at placing Vivos’ therapies in front of more diagnosed patients and building new revenue streams. The company also reported sequential revenue growth in the third quarter of 2025 and continued to expand its leadership team to support operational scaling. For investors, VVOS remains a higher-risk growth story, but one with a distinct clinical niche and a business model that is still being re-shaped toward potentially more durable distribution and revenue generation.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
